Cormedix Inc (CRMD) Stock Price, Quote & News

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was in...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 517 9500

Website: cormedix.com

Address:

389 Interpace Pkwy, Suite 450, Parsippany, United States

Derfzilla Apr. 24 at 6:07 PM

$CRMD

0 · Reply

flabb Apr. 24 at 5:20 PM

$APP sold the one share at 446.76 and used it to set $APLD limit orders $IBRX and $CRMD

0 · Reply

Gencooliveoil Apr. 24 at 5:06 PM

$CRMD $DVA

0 · Reply

Gencooliveoil Apr. 24 at 5:06 PM

$CRMD $ICUI

0 · Reply

Gencooliveoil Apr. 24 at 5:05 PM

$CRMD

0 · Reply

Gencooliveoil Apr. 24 at 5:05 PM

$CRMD $DVA $FMS

0 · Reply

Gencooliveoil Apr. 24 at 5:05 PM

$CRMD never bet against ”da Rock”… As of early 2026, BlackRock, Inc. is a major institutional holder of CorMedix Inc. (CRMD), holding approximately 5.78 million shares, which represents about 7.3% to 7.5% ownership of the company. According to fintel.io, this position makes them one of the top institutional investors in the firm, often appearing in 13F filings. Recent Holdings: BlackRock reported owning 5.78 million shares as of Dec 31, 2025, with a value of roughly $42.3 million. Ownership Stake: Various filings show their ownership percentage around 7.3% to 7.5% of CRMD. Historical Context: Data from stockzoa.com indicates a steady position, with holdings increasing from approximately 3.5 million shares earlier in 2024 to over 5 million by late 2025.

0 · Reply

Noname2022 Apr. 24 at 4:24 PM

$CRMD $FMS Fresenius just confirmed what matters most: infection rates declined but remain high especially in high-risk cohorts, exactly where premium solutions like DefenCath scale https://cme.kidney.org/spa/courses/resource/r830-2026-spring-clinical-meetings/event/home/posters/abstracts?referrer=login&abstractId=9222

2 · Reply

Derek22us Apr. 24 at 4:13 PM

$CRMD If there is a 700 number associated with your trade, you a despicable POS.

0 · Reply

Derek22us Apr. 24 at 4:00 PM

$CRMD Low T, estrogenated, timid sellers, and our 700 share parasites continue to have a leash on the share price. Not enough buy volume to trounce these scavengers.

0 · Reply

CorMedix to Participate in Needham Virtual Healthcare Conference

Mar 5, 2026, 12:58 PM EST - 7 weeks ago

CorMedix stock drops after earnings: is this dip a buy before key catalyst?

Mar 5, 2026, 7:30 AM EST - 7 weeks ago

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 2, 2026, 8:30 AM EST - 7 weeks ago

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

Feb 12, 2026, 8:30 AM EST - 2 months ago

CorMedix to Participate in Upcoming Investor Conferences

Feb 2, 2026, 8:30 AM EST - 2 months ago

CorMedix Therapeutics Announces Share Repurchase Program

Jan 29, 2026, 8:30 AM EST - 3 months ago

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

Jan 9, 2026, 8:30 AM EST - 3 months ago

CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 1:37 PM EST - 3 months ago

Why is CorMedix stock crashing today: is it worth buying on the dip?

Jan 8, 2026, 8:05 AM EST - 3 months ago

CorMedix Therapeutics Announces Leadership and Board Updates

Jan 8, 2026, 8:00 AM EST - 3 months ago

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

Dec 18, 2025, 8:00 AM EST - 4 months ago

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

Nov 12, 2025, 4:05 PM EST - 5 months ago

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

TLPH

Nov 12, 2025, 11:49 AM EST - 5 months ago

CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations

Nov 12, 2025, 7:30 AM EST - 5 months ago

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

Oct 31, 2025, 8:30 AM EDT - 6 months ago

CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

Oct 23, 2025, 8:30 AM EDT - 6 months ago

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

Oct 22, 2025, 4:05 PM EDT - 6 months ago

Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 20, 2025, 9:42 AM EDT - 6 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC RANI RAPT

Oct 20, 2025, 7:30 AM EDT - 6 months ago

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

Sep 29, 2025, 8:30 AM EDT - 7 months ago

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

Sep 8, 2025, 8:30 AM EDT - 8 months ago

CorMedix Announces Strategic Minority Investment in Talphera

TLPH

Sep 8, 2025, 8:30 AM EDT - 8 months ago

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

TLPH

Sep 2, 2025, 7:30 AM EDT - 8 months ago

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

Aug 7, 2025, 10:49 AM EDT - 9 months ago

CorMedix to Buy Melinta Therapeutics for $300 Million

Aug 7, 2025, 7:10 AM EDT - 9 months ago

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

Aug 7, 2025, 7:00 AM EDT - 9 months ago

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

Aug 7, 2025, 7:00 AM EDT - 9 months ago

Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 30, 2025, 2:24 PM EDT - 10 months ago

CorMedix Analyst Says Investors Could Be Further Rewarded

Jun 27, 2025, 9:09 AM EDT - 10 months ago

Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session

CNXC

Jun 27, 2025, 8:00 AM EDT - 10 months ago

CorMedix Inc. Announces Pricing of Public Offering of Common Stock

Jun 26, 2025, 4:01 PM EDT - 10 months ago

CorMedix Inc. Announces Proposed Public Offering of Common Stock

Jun 23, 2025, 7:30 AM EDT - 10 months ago

CorMedix inc. Announces Customer Implementation

May 30, 2025, 8:30 AM EDT - 11 months ago

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

May 15, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Participate in the RBC Global Healthcare Conference

May 6, 2025, 7:30 AM EDT - 1 year ago

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

Apr 8, 2025, 7:30 AM EDT - 1 year ago

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

Apr 2, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 7:30 AM EDT - 1 year ago

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 24, 2025, 9:21 AM EDT - 1 year ago

CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Derfzilla Apr. 24 at 6:07 PM

$CRMD

0 · Reply

flabb Apr. 24 at 5:20 PM

$APP sold the one share at 446.76 and used it to set $APLD limit orders $IBRX and $CRMD

0 · Reply

Gencooliveoil Apr. 24 at 5:06 PM

$CRMD $DVA

0 · Reply

Gencooliveoil Apr. 24 at 5:06 PM

$CRMD $ICUI

0 · Reply

Gencooliveoil Apr. 24 at 5:05 PM

$CRMD

0 · Reply

Gencooliveoil Apr. 24 at 5:05 PM

$CRMD $DVA $FMS

0 · Reply

Gencooliveoil Apr. 24 at 5:05 PM

0 · Reply

Noname2022 Apr. 24 at 4:24 PM

2 · Reply

Derek22us Apr. 24 at 4:13 PM

$CRMD If there is a 700 number associated with your trade, you a despicable POS.

0 · Reply

Derek22us Apr. 24 at 4:00 PM

$CRMD Low T, estrogenated, timid sellers, and our 700 share parasites continue to have a leash on the share price. Not enough buy volume to trounce these scavengers.

0 · Reply

flabb Apr. 24 at 3:58 PM

$CRMD 7.37

0 · Reply

flabb Apr. 24 at 3:52 PM

$CRMD i just got power and added 7.39

0 · Reply

ReturnOfEsquire Apr. 24 at 3:13 PM

$CRMD When I bought this trash Intel was at 19. I chose this pig instead. Great move.

3 · Reply

JackNapier22 Apr. 24 at 3:03 PM

$CRMD wow, AMD was $88 on liberation day. Anyone with a remote idea about the AI revolution knew it was going way higher…. and yet people still wait around for this dog. Time is money and this is a time gobbler.

1 · Reply

Noname2022 Apr. 24 at 2:07 PM

$CRMD $DVA $FMS

0 · Reply

Gencooliveoil Apr. 24 at 2:07 PM

$CRMD I rather listen to someone who stalks message boards all day under multiple aliases. Your parents must be very proud of your career choice. Bullish

1 · Reply

CRMDepressed Apr. 24 at 1:58 PM

$CRMD look at these shameless bullshit spammers man.

0 · Reply

Gencooliveoil Apr. 24 at 1:57 PM

$CRMD CorMedix Board & Executive Ties to Pfizer Current and former CorMedix leaders with notable Pfizer backgrounds include: Gregory Duncan (Independent Director): Appointed to the Board in November 2020. He spent approximately 18 years at Pfizer in various senior roles, including Senior Vice President of US Marketing and President of Pfizer's Latin America business. Matthew Duffy (Former Director): Joined the Board in 2011. He began his career at Pfizer, serving in executive positions in sales, marketing, and product management. Notably, he was the first product manager for Viagra. Donna Ucci (SVP, Head of Global Quality): While not a board member, she joined CorMedix in 2022 as a senior executive. Her background includes quality leadership experience at Pfizer, along with roles at Impax and Allergan.

0 · Reply

CRMDepressed Apr. 24 at 1:56 PM

$CRMD noname should get lynched

1 · Reply

Noname2022 Apr. 24 at 1:24 PM

$CRMD $ICUI ***draft gudeline update*** On page 275; DefenCath mentioned for use in high infection risk population… couldn’t find any mention of Clearguard HD https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-AKI-AKD-Guideline-Public-Review-Draft-March-2026.pdf

0 · Reply

flabb Apr. 24 at 1:17 PM

$CRMD 7.28 and 7.30 filled

0 · Reply

flabb Apr. 24 at 1:03 PM

$CRMD 7.35 7.36 and 7.37 orders filled

0 · Reply

Market Cap	579.44M
Revenue (ttm)	311.71M
Net Income (ttm)	163.06M
EPS (ttm)	N/A
PE Ratio	4.26
Forward PE	11.18
Profit Margin	52.31%
Debt to Equity Ratio	0.00

Volume	656,500
Avg Vol	1,330,920
Day's Range	N/A - N/A
Shares Out	79.05M
Stochastic %K	56%
Beta	1.41
Analysts	Strong Sell
Price Target	$14.57